88 related articles for article (PubMed ID: 26184701)
1. Time course of cytokines, hemodynamic and metabolic parameters during hyperthermic intraperitoneal chemotherapy.
Coccolini F; Corbella D; Finazzi P; Brambillasca P; Benigni A; Prussiani V; Ceresoli M; Manfredi R; Poiasina E; Bertoli P; Catena F; Bianchetti A; Bontempelli M; Lorini LF; Sonzogni V; Ansaloni L
Minerva Anestesiol; 2016 Mar; 82(3):310-9. PubMed ID: 26184701
[TBL] [Abstract][Full Text] [Related]
2. Time course of cytokines, hemodynamic and metabolic parameters during hyperthermic intraperitoneal chemotherapy.
Coccolini F; Corbella D; Finazzi P; Brambillasca P; Benigni A; Prussiani V; Ceresoli M; Manfredi R; Poiasina E; Bertoli P; Catena F; Bianchetti A; Bontempelli M; Lorini LF; Sonzogni V; Ansaloni L
Minerva Anestesiol; 2015 Jul; ():. PubMed ID: 26154446
[TBL] [Abstract][Full Text] [Related]
3. Hemodynamic Monitoring During Heated Intraoperative Intraperitoneal Chemotherapy Using the FloTrac/Vigileo System.
Mavroudis C; Alevizos L; Stamou KM; Vogiatzaki T; Eleftheriadis S; Korakianitis O; Tentes AA; Iatrou C
Int Surg; 2015 Jun; 100(6):1033-9. PubMed ID: 25590363
[TBL] [Abstract][Full Text] [Related]
4. Hyperthermic intraperitoneal chemotherapy plus simultaneous versus staged cytoreductive surgery for gastric cancer with occult peritoneal metastasis.
Wu X; Li Z; Li Z; Jia Y; Shan F; Ji X; Bu Z; Zhang L; Wu A; Ji J
J Surg Oncol; 2015 Jun; 111(7):840-7. PubMed ID: 25864884
[TBL] [Abstract][Full Text] [Related]
5. The use of cardiac output monitoring to guide the administration of intravenous fluid during hyperthermic intraperitoneal chemotherapy.
Thanigaimani K; Mohamed F; Cecil T; Moran BJ; Bell J
Colorectal Dis; 2013 Dec; 15(12):1537-42. PubMed ID: 24119169
[TBL] [Abstract][Full Text] [Related]
6. The Global End-Diastolic Volume (GEDV) Could Be More Appropiate to Fluid Management Than Central Venous Pressure (CVP) During Closed Hyperthermic Intrabdominal Chemotherapy with CO
Redondo FJ; Padilla D; Villarejo P; Baladron V; Faba P; Sánchez S; Muñoz-Rodríguez JR; Bejarano N
J Invest Surg; 2018 Aug; 31(4):321-327. PubMed ID: 28557569
[TBL] [Abstract][Full Text] [Related]
7. Trends in cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for the treatment of synchronous peritoneal carcinomatosis of colorectal origin in the Netherlands.
Razenberg LG; van Gestel YR; Creemers GJ; Verwaal VJ; Lemmens VE; de Hingh IH
Eur J Surg Oncol; 2015 Apr; 41(4):466-71. PubMed ID: 25680955
[TBL] [Abstract][Full Text] [Related]
8. Cytoreductive surgery and hyperthermic intra-peritoneal chemotherapy treatment of colorectal peritoneal metastases: cohort analysis of high volume disease and cure rate.
Cashin PH; Dranichnikov F; Mahteme H
J Surg Oncol; 2014 Aug; 110(2):203-6. PubMed ID: 24846340
[TBL] [Abstract][Full Text] [Related]
9. Hemodynamic and cardiovascular problems during modified hyperthermic intraperitoneal perioperative chemotherapy.
Rankovic VI; Masirevic VP; Pavlov MJ; Ceranic MS; Milenkovic MG; Simic AP; Kecmanovic DM
Hepatogastroenterology; 2007 Mar; 54(74):364-6. PubMed ID: 17523275
[TBL] [Abstract][Full Text] [Related]
10. Intra-abdominal pressure, Cardiac Index and vascular resistance during hyperthermic intraperitoneal chemotherapy: a prospective observational study.
Schluermann CN; Hoeppner J; Benk C; Schmidt R; Loop T; Kalbhenn J
Minerva Anestesiol; 2016 Feb; 82(2):160-9. PubMed ID: 25971283
[TBL] [Abstract][Full Text] [Related]
11. Cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy with oxaliplatin for peritoneal carcinomatosis arising from colorectal cancer.
Gervais MK; Dubé P; McConnell Y; Drolet P; Mitchell A; Sideris L
J Surg Oncol; 2013 Dec; 108(7):438-43. PubMed ID: 24018983
[TBL] [Abstract][Full Text] [Related]
12. Treatment of ovarian metastases of colorectal and appendiceal carcinoma in the era of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy.
Kuijpers AM; Mehta AM; Aalbers AG; van Driel WJ; Boot H; Verwaal VJ
Eur J Surg Oncol; 2014 Aug; 40(8):937-42. PubMed ID: 24630923
[TBL] [Abstract][Full Text] [Related]
13. Repeated cytoreductive surgery (CRS) with hyperthermic intraperitoneal chemotherapy (HIPEC) in patients with recurrent peritoneal carcinomatosis.
Vassos N; Förtsch T; Aladashvili A; Hohenberger W; Croner RS
World J Surg Oncol; 2016 Feb; 14(1):42. PubMed ID: 26912149
[TBL] [Abstract][Full Text] [Related]
14. Predictive and prognostic survival factors in peritoneal carcinomatosis from appendiceal cancer after cytoreductive surgery with hyperthermic intraperitoneal chemotherapy.
Jimenez W; Sardi A; Nieroda C; Sittig M; Milovanov V; Nunez M; Aydin N; Gushchin V
Ann Surg Oncol; 2014 Dec; 21(13):4218-25. PubMed ID: 24986239
[TBL] [Abstract][Full Text] [Related]
15. Predictors of progression in high-grade appendiceal or colorectal peritoneal carcinomatosis after cytoreductive surgery and hyperthermic intraperitoneal chemotherapy.
Baumgartner JM; Tobin L; Heavey SF; Kelly KJ; Roeland EJ; Lowy AM
Ann Surg Oncol; 2015 May; 22(5):1716-21. PubMed ID: 25145504
[TBL] [Abstract][Full Text] [Related]
16. Extreme cytoreductive surgery and hyperthermic intraperitoneal chemotherapy: Outcomes from a single tertiary center.
Berger Y; Aycart S; Mandeli JP; Heskel M; Sarpel U; Labow DM
Surg Oncol; 2015 Sep; 24(3):264-9. PubMed ID: 26143715
[TBL] [Abstract][Full Text] [Related]
17. Postoperative outcomes of laparoscopic vs open cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy for treatment of peritoneal surface malignancies.
Passot G; Bakrin N; Isaac S; Decullier E; Gilly FN; Glehen O; Cotte E
Eur J Surg Oncol; 2014 Aug; 40(8):957-62. PubMed ID: 24209429
[TBL] [Abstract][Full Text] [Related]
18. Melphalan: a promising agent in patients undergoing cytoreductive surgery and hyperthermic intraperitoneal chemotherapy.
Sardi A; Jimenez W; Nieroda C; Sittig M; Shankar S; Gushchin V
Ann Surg Oncol; 2014 Mar; 21(3):908-14. PubMed ID: 24276642
[TBL] [Abstract][Full Text] [Related]
19. The role of baseline inflammatory-based scores and serum tumor markers to risk stratify pseudomyxoma peritonei patients treated with cytoreduction (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC).
Kusamura S; Baratti D; Hutanu I; Gavazzi C; Morelli D; Iusco DR; Grassi A; Bonomi S; Virzì S; Haeusler E; Deraco M
Eur J Surg Oncol; 2015 Aug; 41(8):1097-105. PubMed ID: 26026742
[TBL] [Abstract][Full Text] [Related]
20. Evaluation of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in a community setting: A cost-utility analysis of a hospital's initial experience and reflections on the health care system.
Naffouje SA; O'Donoghue C; Salti GI
J Surg Oncol; 2016 Apr; 113(5):544-7. PubMed ID: 26750613
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
